SynthesisEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2026
Extracorporeal shock wave therapy (ESWT) for treatment of osteonecrosis of the femoral head: a systematic review and meta-analysis.
Synthesis in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis systematic review and meta-analysis evaluated the clinical and radiological effectiveness of extracorporeal shock wave therapy (ESWT) for Osteonecrosis of the femoral head (ONFH).
methodsWe systematically searched PubMed, Embase, and CENTRAL for studies evaluating ESWT in adults with ONFH, adhering to PRISMA guidelines. The primary outcomes analyzed were changes in visual analogue scale (VAS) for pain and Harris hip score (HHS) for function, along with radiological changes. A meta-analysis was performed using fixed or random-effects models to calculate pooled standardized mean differences (SMD). Study quality was critically appraised using the RoB 2 and ROBINS-I tools.
resultsTwenty-six studies, encompassing 1584 patients (2241 hips), met the inclusion criteria. The pooled analysis demonstrated that ESWT was associated with a significant reduction in pain on the VAS (SMD, 4.01; 95% CI 3.53–4.50; p < 0.0001) and a significant improvement in hip function on the HHS (SMD, 18.97; 95% CI 15.60–22.33; p < 0.0001). Direct comparisons also favored ESWT over non-ESWT control interventions. While pooled data showed no significant change in ARCO stage, ESWT was linked to reduced bone marrow edema and a low rate of conversion to total hip arthroplasty. The quality assessment, however, revealed that a majority of studies presented a moderate to serious risk of bias.
conclusionESWT is a potential non-operative treatment for early-stage ONFH, delivering significant pain relief and functional improvement. The considerable heterogeneity and methodological limitations across the evidence base highlight an urgent need for standardized treatment protocols and large-scale, high-quality randomized controlled trials.
Indexed as
Identifiers
41984269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.